Literature DB >> 10631691

Palliative chemotherapy: no longer a contradiction in terms.

V R Archer1, L J Billingham, M H Cullen.   

Abstract

Palliative chemotherapy is defined as treatment in circumstances where the impact of intervention is insufficient to result in major survival advantage, but does affect improvement in terms of tumor-related symptoms, and where the palliation/toxicity trade-off from treatment clearly favors symptom relief. The role of chemotherapy in circumstances where little or no survival benefit is anticipated remains controversial. This is despite the mounting body of evidence in favor of its use for symptom palliation. The notion persists that outcomes other than significant survival benefit are not valid, because of firmly held perceptions of toxicity. Studies of chemotherapeutic palliation using valid measures of quality of life, show that patients may be willing to accept some side effects of treatment, as long as they gain relief from tumor-related symptoms. The aims of this review are to present the case for palliative chemotherapy, to highlight the areas of progress which have made this feasible, and to provide guidance with regard to its appropriate use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10631691

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  14 in total

1.  Does palliative chemotherapy palliate?

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 2.  Chemotherapy for cancer patients who present late.

Authors:  Stella J Bowcock; Charles D Shee; Saad M B Rassam; Peter G Harper
Journal:  BMJ       Date:  2004-06-12

3.  Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents.

Authors:  Leigh A Graham; Jimmy Suryadi; Tiffany K West; Gregory L Kucera; Ulrich Bierbach
Journal:  J Med Chem       Date:  2012-08-17       Impact factor: 7.446

4.  Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior?

Authors:  Gianmauro Numico; Antonio Trogu; Antonella Cristofano; Alessandro Mozzicafreddo; Giulia Courthod; Pierfrancesco Franco; Nicola Silvestris
Journal:  Support Care Cancer       Date:  2014-05-11       Impact factor: 3.603

Review 5.  Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning.

Authors:  M Cullen
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

6.  Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life.

Authors:  Sun Young Rha; Jiyeon Lee
Journal:  Support Care Cancer       Date:  2016-12-28       Impact factor: 3.603

Review 7.  Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway.

Authors:  Iman W Achkar; Nabeel Abdulrahman; Hend Al-Sulaiti; Jensa Mariam Joseph; Shahab Uddin; Fatima Mraiche
Journal:  J Transl Med       Date:  2018-04-11       Impact factor: 5.531

8.  Redesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study.

Authors:  Amanda J Pickard; Fang Liu; Thomas F Bartenstein; Laura G Haines; Keith E Levine; Gregory L Kucera; Ulrich Bierbach
Journal:  Chemistry       Date:  2014-10-10       Impact factor: 5.236

9.  Patient-Reported and End-of-Life Outcomes Among Adults With Lung Cancer Receiving Targeted Therapy in a Clinical Trial of Early Integrated Palliative Care: A Secondary Analysis.

Authors:  Laura A Petrillo; Areej El-Jawahri; Emily R Gallagher; Vicki A Jackson; Jennifer S Temel; Joseph A Greer
Journal:  J Pain Symptom Manage       Date:  2021-02-20       Impact factor: 3.612

10.  What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study.

Authors:  Suzanne Audrey; Julian Abel; Jane M Blazeby; Stephen Falk; Rona Campbell
Journal:  BMJ       Date:  2008-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.